Ionis Pharmaceuticals Inc. Common Stock (IONS)
Stock · NASDAQ · Health Care
$42.94as of 10/16/2026
Price chart
Active signals
IONS Signal Track Record
How signals performed across all stocks →What IONS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 27 | -1.4% | 41% | September 18, 2026 |
| Bollinger Band Breakout | 25 | +0.4% | 52% | August 17, 2026 |
| Bollinger Band Breakdown | 18 | -4.2% | 39% | September 14, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -0.1% | 46% | June 17, 2026 |
| Any 20-session window (baseline) | +0.5% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About IONS
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medi…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 1,480
- Website
- www.ionis.com/
Fundamentals
- 1-day range
- $43.11$44.65
- Market cap
- $9.06B
- P/E (trailing)
- —
- P/E (forward)
- -38.86
- EPS (trailing)
- $-3.47
- Dividend yield
- —
- Beta
- 0.38
- Avg. volume
- 3.29M
How Ionis Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
23 analyst ratings
Ionis Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- IONSIonis Pharmaceuticals Inc. Common Stock$42.94▼ 2.67%Market cap $9.06BP/E —$42.08$86.74
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals Inc. Common Stock | $9.06B | — | $42.94 | ▼ 2.67% | $42.08$86.74 |
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Ionis Pharmaceuticals Receives EMA CHMP Positive Opinion Recommending Indication Extension For TRYNGOLZA For Treatment Of Adult Patients With Severe Hypertriglyceridemiabenzinga · 10/16/2026
- Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio SetbacksYahoo · 9/19/2026
- Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?Yahoo · 9/18/2026
- Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?Yahoo · 9/18/2026
- Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage TrialYahoo · 9/17/2026
- Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?Yahoo · 9/17/2026
- Novartis Suffers Another Setback After Two High-Profile Surprises Hammered SharesYahoo · 9/16/2026
- Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 9/16/2026
- Baron Health Care Fund Q2 2026 Portfolio ActivitySeekingAlpha · 9/16/2026
Insider Activity
Insider Actions →- Michael R. Hayden · July 31, 2026 · Buy5.0K @ $51.6
- Michael R. Hayden · July 30, 2026 · Buy15.0K @ $53.38
- Reikes Peter N · July 15, 2026 · Grant3.4K
- HANTSON LUDWIG · July 15, 2026 · Grant3.4K
- Joan E. Herman · July 15, 2026 · Option Exercise5.2K
- BERTHELSEN SPENCER R · July 15, 2026 · Option Exercise5.2K
- BENNETT C FRANK · July 7, 2026 · Sale15.0K @ $85.46
- BENNETT C FRANK · July 7, 2026 · Sale5.5K @ $83.58
- Kordasiewicz Holly B. · July 7, 2026 · Sale362 @ $84.3
- Diaz Allene M. · July 7, 2026 · Option Exercise10.1K @ $47.11
- Diaz Allene M. · July 7, 2026 · Sale10.1K @ $85.42
- BENNETT C FRANK · July 7, 2026 · J15.0K
- Diaz Allene M. · July 1, 2026 · Grant2.3K
- Diaz Allene M. · July 1, 2026 · Grant5.4K
- Michael J. Yang · July 1, 2026 · Grant2.3K
Institutional Ownership
March 31, 2026
- Total shares held
- 164.14M
- Total value held
- $11.49B
- Institutional holders
- 487
- Unknown24.56M
- Unknown21.19M
- Unknown10.44M
- Unknown7.12M
- Unknown6.39M
- Unknown6.16M
- Unknown5.86M
- Unknown4.00M
- Unknown3.98M
- Unknown3.80M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Cathie Wood adds to Ionis position amid RNA sector interest
Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.
Cathie Wood adds to Ionis position amid RNA sector interest. Cathie Wood has increased her holdings in Ionis Pharmaceuticals as part of a broader bet on two stocks. This move highlights continued investor interest in RNA therapeutics, a sector currently drawing attention for its innovation potential. While the stock is trading near its 52-week low, the average analyst target remains significantly higher than the current price.